COMMUNIQUÉS West-GlobeNewswire

Cue Biopharma Announces CEO Transition
27/03/2026
Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company [...]
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
27/03/2026
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and [...]
Preliminary Results for the Year Ended 31 December 2025
27/03/2026
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX [...]
Leo International Precision Health AG: Mr Leo Wang, Acquisition
27/03/2026
Leo International Precision Health AG: Mr Leo Wang, Acquisition Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 27. Mar [...]
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
27/03/2026
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
NTG Nordic Transport Group A/S – Annual General Meeting 2026
27/03/2026
Company announcement no. 7 – 26 27 March 2026 NTG Nordic Transport Group A/S – Annual General Meeting 2026 Today, at 14:00, NTG Nordic Transport Group A/S (“NTG” or the “Company”), CVR no. 12 54 61 06, held its Annual [...]
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
27/03/2026
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization, stability [...]
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
27/03/2026
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, N.J., March 27, [...]
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
27/03/2026
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB [...]
EUROAPI - Mise à disposition du Document d’Enregistrement Universel 2025
27/03/2026
Communiqué de presse Mise à disposition du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris - Le 27 mars 2026 - EUROAPI annonce la publication de son Document d’Enregistrement [...]
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
27/03/2026
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris [...]
Jushi Holdings Inc. Refinances Former 1st Lien Credit Facility and Former 2nd Lien Credit Facility with US$160 Million Non-Dilutive Debt Financing
27/03/2026
Adds Cash to the Balance Sheet The Company to Report Fourth Quarter 2025 Financial Results on March 31, 2026 BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH [...]
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
27/03/2026
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 [...]
EUROAPI - Availability of the 2025 Universal Registration Document
27/03/2026
Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Registration Document in [...]
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
27/03/2026
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer and vascular [...]
Vor Bio Announces $75 Million Private Placement with TCGX
27/03/2026
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase [...]
OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
27/03/2026
Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the [...]
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
27/03/2026
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle [...]
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
27/03/2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]

Pages